Clinical Trial: Vorasidenib Study in Pediatric Participants With Grade 2 Astrocytoma or Oligodendroglioma With an IDH1 or IDH2 Mutation

U.S., Dec. 17 -- ClinicalTrials.gov registry received information related to the study (NCT07286292) titled 'Vorasidenib Study in Pediatric Participants With Grade 2 Astrocytoma or Oligodendroglioma With an IDH1 or IDH2 Mutation' on Dec. 10.

Brief Summary: The objective of this study is to evaluate the safety, tolerability, efficacy profile, and effect on growth and development of vorasidenib in pediatric participants aged 12 to = 40 kg OR 20mg taken orally daily for participants weighing >= 25 kg to < 40 kg

Recruitment Status: NOT_YET_RECRUITING

Sponsor: Institut de Recherches Internationales Servier (I.R.I.S.)

Published by HT Digital Content Services with permission from Health Daily Digest....